NIH chief Francis Collins told a gathering of pharmaceutical scientists his agency needs to take an engineering approach to eliminate anything that slows drug development. Early discovery and preclinical development are well-known bottlenecks, and Collins said identifying new targets for approved drugs or compounds abandoned in the clinical stage will help the industry get more drugs to market. Story